The remarkable advances in melanoma immunotherapy occasioned by the development of CTLA-4 and PD-1/PDL1 checkpoint inhibition underscores the importance of understanding potential contributions of melanoma-elaborated cytokines such as IL32 [61]. This evidence concerns the gene CD274 and melanoma.